KalVista CEO Benjamin Palleiko RSU Vesting and Tax Withholding Sale

This Form 4 filing reports equity transactions by Benjamin L. Palleiko, CEO and Director of KalVista Pharmaceuticals, Inc. On April 16, 2026, 20,312 restricted stock units (RSUs) vested and converted to common stock at $0 per share, increasing Palleiko's direct holdings to 472,127 shares. Each RSU represents a contingent right to receive one share of common stock upon settlement. The RSUs vest quarterly over four years, with 1/16th vesting each quarter starting April 16, 2026. On April 17, 2026, Palleiko sold 9,550 shares at $20.2163 per share to cover tax withholding obligations related to the RSU vesting, reducing his direct holdings to 462,577 shares. The sale was specifically for tax withholding purposes through a "sell to cover" transaction and was not a discretionary trade. Palleiko remains a significant shareholder with substantial direct ownership in the company.